COL6A2

Across TCGA pan-cancer cohorts, COL6A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COL6A2 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COL6A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated COL6A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where COL6A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.275	0.461	.002	32	view →
CCRCC	DFS	Median	II,III,IV	0.779	0.459	.006	28	view →
LSCC	DFS	Quartile	All	0.564	0.870	.006	21	view →
GBM	OS	Quartile	All	0.729	0.975	.004	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COL6A2–PDAC (OS)

Open the PDAC breakdown →